ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Results of Operations and Financial Condition

ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02 Results of Operations and Financial
Conditions

On May10, 2017, Adaptimmune Therapeutics plc (the Company) issued
a press release announcing its financial results for the first
quarter ended March31, 2017. The text of the press release is
attached as Exhibit99.1 and is incorporated by reference herein.

Item 8.01 Other Events.

On May10, 2017, the Company also announced that it has initiated
its alpha fetoprotein SPEAR T-cell study in patients with locally
advanced or metastatic hepatocellular carcinoma, the sixth most
common cancer worldwide. The text of the press release is
attached as Exhibit99.2 and is incorporated by reference herein.

The information contained in Item 2.02 and Item 8.01 of this
Form8-K, including the attached Exhibit99.1 and Exhibit99.2,
shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or incorporated by reference in any filing made by the Company
under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by the Company by specific
reference in such a filing.

Item 9.01 Financial Statements and
Exhibits.

(d) Exhibits. The following exhibits are furnished as part of
this Report on Form8-K:

ExhibitNo.

DescriptionofExhibit

99.1

Press Release dated May10, 2017

99.2

Press Release dated May10, 2017


About ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP)

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company’s TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.

ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Recent Trading Information

ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) closed its last trading session down -0.07 at 4.93 with 270,332 shares trading hands.

An ad to help with our costs